Key differences at a glance
- What they are:
- Cagrilintide: Long-acting amylin analogue in clinical development focused on satiety and gastric emptying.
- Tirzepatide: Dual GIP/GLP‑1 receptor agonist affecting appetite, gastric emptying and glycaemic control; available by prescription.
- Weight loss evidence:
- Tirzepatide: Large trials report substantial average weight loss at higher doses over ~72 weeks.
- Cagrilintide: Promising signals, especially when combined with semaglutide in trials; head-to-head vs tirzepatide not available.
- Tolerability: Both can cause gastrointestinal effects (nausea, fullness, constipation or diarrhoea), usually during dose escalation.
- Availability in Australia: Tirzepatide is prescription-only; cagrilintide is investigational with evolving access.
How they work: mechanisms that matter
Cagrilintide (amylin analogue)
- Mimics/supplements amylin signalling to increase satiety and reduce food reward.
- Slows gastric emptying, helping people feel full with smaller portions.
- Investigated as a weekly injection, including in combination with GLP‑1 medicines.
Tirzepatide (dual GIP/GLP‑1 agonist)
- Activates both GIP and GLP‑1 receptors to reduce appetite and improve post‑meal insulin responses.
- Slows gastric emptying and may reduce cravings via central satiety pathways.
- Once‑weekly injection with stepwise dose escalation to improve tolerability.
Weight loss results: what studies suggest
- Tirzepatide: In large obesity trials, higher maintenance doses over ~72 weeks delivered substantial average weight loss, with many participants achieving double‑digit percentage reductions when supported by diet and activity guidance.
- Cagrilintide: Early-phase data show meaningful weight loss signals. Notably, combination studies with semaglutide reported larger average reductions than semaglutide alone in trial settings. Robust head‑to‑head studies versus tirzepatide have not been reported.
Individual outcomes vary based on dose, adherence, side effects, metabolic status and clinical guidance. Always discuss realistic expectations with a practitioner.
Side effects and safety signals
- Common effects for both: nausea, vomiting, diarrhoea or constipation, early fullness, abdominal discomfort, dizziness or fatigue—often during dose titration.
- Warnings discussed with GLP‑1/GIP therapies: risk of gallbladder issues, rare pancreatitis, and a boxed/precautionary warning about thyroid C‑cell tumours in rodents (human relevance uncertain). Not recommended with history of medullary thyroid carcinoma or MEN2.
- Amylin analogues: nausea and fullness are common initially; slow titration and dietary adjustments are typically used to improve tolerability in trials.
This information is general and not medical advice. Seek urgent care for severe or worsening symptoms.
Dosing, escalation and adherence
- Tirzepatide: Once‑weekly subcutaneous injection with staged increases from a low starting dose to a personalised maintenance dose.
- Cagrilintide: Investigational weekly dosing with titration evaluated in studies. Final approved protocols (if approved) may differ from trial designs.
- Do not stack or combine medicines without medical direction—especially dual agonists and amylin analogues—because tolerability and safety depend on careful titration and monitoring.
Who each option may suit
- When appetite and portion control dominate: Amylin‑based approaches like cagrilintide (when available) may be explored for satiety‑focused support.
- When weight plus glucose or insulin resistance matter: Tirzepatide’s dual GIP/GLP‑1 action is often discussed for combined metabolic and weight effects.
- Red flags and contraindications commonly discussed:
- History of medullary thyroid carcinoma or MEN2 (GLP‑1 class precaution).
- History of pancreatitis, severe GI disease, or gallbladder disease—requires careful medical review.
- Pregnancy, breastfeeding or planning pregnancy—seek specialist advice.
Australian access, legal status and cost
- Tirzepatide: Prescription‑only in Australia. Indications, supply and brand availability evolve; pricing varies by clinic and pharmacy. See:
- Cagrilintide: Investigational. Routine pharmacy access is not established in Australia at this time. Learn more:
Can you combine them? What about “cagriSema” and other stacks?
- Trials combining cagrilintide with semaglutide have shown promising additional weight loss compared with semaglutide alone.
- These combinations are not widely available in Australia. Protocols and doses used in studies may differ from any future approved products.
- Combining tirzepatide with amylin analogues has not been established as standard care. Do not experiment with combinations without prescriber oversight.
Explore related comparisons and guides: Cagrilintide vs Semaglutide, Semaglutide vs Tirzepatide Weight Loss, Retatrutide vs Tirzepatide, GLP‑1 Australia Guide.
Alternatives to discuss if one isn’t suitable
- Semaglutide (GLP‑1): What Is Semaglutide?, Benefits, Dosage, Side Effects.
- Retatrutide (triple agonist, investigational): What Is Retatrutide?, Benefits, Side Effects.
- Weight‑loss injection overview: Weight Loss Injections Australia.
Frequently asked questions
What is the main difference between cagrilintide and tirzepatide?
Cagrilintide is an amylin analogue under investigation for appetite control and satiety, while tirzepatide is a dual GIP/GLP‑1 agonist approved for type 2 diabetes and used for weight management under medical care.
Which is better for weight loss?
Large trials show tirzepatide can deliver substantial average weight loss at higher doses over ~72 weeks. Cagrilintide shows promising signals—especially when combined with semaglutide in trials—but there are no direct head‑to‑head data versus tirzepatide.
Are side effects different?
Both can cause gastrointestinal symptoms during dose escalation. GLP‑1/GIP agents have specific warnings (e.g., thyroid C‑cell tumour risk in rodents, pancreatitis). Individual tolerability varies; a clinician can personalise titration and monitoring.
Is cagrilintide available in Australia?
It remains investigational and is not routinely available via standard pharmacy channels. Access, if any, would be through clinical pathways. Check current status with a prescriber.
How do I access tirzepatide in Australia?
Through a prescription. Availability, indications and costs change over time. See our guides: Tirzepatide Prescription Australia and Tirzepatide Cost Australia.
Can I combine amylin analogues with GLP‑1 or dual agonists?
Only under specialist supervision. Some combinations have been studied in clinical trials, but they are not standard consumer therapies in Australia.
Final takeaway
Cagrilintide vs tirzepatide is ultimately appetite‑first amylin signalling vs dual GIP/GLP‑1 metabolic signalling. Tirzepatide has large-scale evidence and prescription access; cagrilintide remains investigational with compelling research signals, especially in combinations. An experienced prescriber can match mechanisms, evidence and safety to your health profile.
Speak with an Australian clinician
Compare options, check eligibility and get guidance on availability, dosing and safety. Complete the form and a provider will contact you.